Back to search
FDAFDA · Food and drugs·Recall number D-0596-2026

Buprenorphine HCl, CIII, Injection, 0.3 mg/mL, 5 x 1 mL Single Dose Vials per Carton, Rx Only, For Intramuscular or Intravenous use, Manufactured for: Endo USA, Malvern, PA 19355, NDC 42023-179-05

Published June 24, 2026 · Recall initiated: June 12, 2026

Summary

FDA records drug Class II recall D-0596-2026, published June 24, 2026 and initiated June 12, 2026. Recalling firm: Par Health USA, LLC; Status: Ongoing; Reported quantity: 46,334 units; Lot: Lot #: 82886, exp 09/30/2026; 89646, exp 05/31/2027. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Crystallization; identified as Buprenorphine free base

What to do

Voluntary: Firm initiated · Letter

Get an email if BUPRENORPHINE HYDROCHLORIDE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
BUPRENORPHINE HYDROCHLORIDE
Manufacturer
Par Health USA, LLC
Distributor
Nationwide in the USA.
Lot
Lot #: 82886, exp 09/30/2026; 89646, exp 05/31/2027
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Buprenorphine HCl, CIII, Injection, 0.3 mg/mL, 5 x 1 mL Single Dose Vials per Carton, Rx Only, For Intramuscular or Intravenous use, Manufactured for: Endo USA, Malvern, PA 19355, NDC 42023-179-05 recalled?

Yes. FDA published recall D-0596-2026 on June 24, 2026. Reported hazard: Crystallization; identified as Buprenorphine free base

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: BUPRENORPHINE HYDROCHLORIDE.